Causal Inference in a Placebo-Controlled Clinical Trial With Binary Outcome and Ordered Compliance
二元结局与有序依从性的安慰剂对照临床试验因果推断AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确讨论部分依从下的潜在治疗反应、因果参数及其识别限制。
二元结局与有序依从性的安慰剂对照临床试验因果推断AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
We propose a likelihood-based method to analyze the causal effect of partial compliance (i.e., unplanned partial exposure to treatment or placebo) in the LRC-CPPT data, a prevention trial with long term follow-up previously analyzed by Efron and Feldman. Initially, we construct ordered compliance categories and dichotomize response. Assuming increased exposure to cholestyramine does not increase cholesterol, we estimate exposure—response curves in different compliance subsets. Subjects in different arms with similar levels of compliance to the assignment may have a different placebo prognosis (i.e., success probability under a possible zero exposure level). The sole assumption that the placebo group reflects response to zero exposure for the treatment group as a whole allows estimation of a causal parameter in a special case only. When a single parameter represents the association between responses to possible treatment exposures and treatment compliance, simple estimates are derived for a set of causal parameters. The example is analyzed in detail, and more general applicability and extensions of the method are discussed.